论文部分内容阅读
目的探讨抗苗勒氏管激素(AMH)水平对年龄超过40岁的患者行体外受精-胚胎移植、卵胞浆内单精子注射(IVF/ICSI-ET)周期妊娠结局的预测意义。方法我们回顾性分析了我院生殖中心就诊的188名年龄在40岁到44岁接受IVF/ICSI新鲜胚胎移植周期不孕患者的医疗记录。患者随机分为A组,与AMH水平<1ng/ml(n=97),B组与AMH水平≥1ng/ml(n=91)。我们比较了两组的临床妊娠率(CPR),并进行了逻辑回归分析。结果 A组的临床妊娠率明显低于B组(24.2%比7.2%,P﹤0.001),多因素Logistic回归分析,AMH水平是对临床妊娠率显著影响的唯一因素(优势比,1.510;95%置信区间,1.172-1.947)。结论我们的研究表明,AMH水平预测年龄超过40岁不孕患者临床妊娠结局。
Objective To investigate the predictive value of anti-mullerian hormone (AMH) levels in IVF / ICSI-ET cycles in patients over 40 years of age undergoing in vitro fertilization-embryo transfer (IVF / ICSI-ET). METHODS: We retrospectively analyzed the medical records of 188 infertile women aged 40 to 44 who underwent IVF / ICSI fresh embryo transfer at our reproductive center. Patients were randomly divided into group A with AMH levels <1 ng / ml (n = 97) and group B with AMH levels ≥ 1 ng / ml (n = 91). We compared the clinical pregnancy rates (CPR) between the two groups and performed logistic regression analysis. Results The clinical pregnancy rate in group A was significantly lower than that in group B (24.2% vs 7.2%, P <0.001). Multivariate Logistic regression analysis showed that the AMH level was the only factor significantly influencing clinical pregnancy rate (odds ratio, 1.510; 95% Confidence interval, 1.172-1.947). Conclusions Our study showed that AMH levels predict clinical pregnancy outcomes in women over 40 years of age who are infertile.